Preparing for a New Era: Insights from the 2026 National Celiac Disease Policy Symposium

On Friday, June 12, 2026, the landscape of celiac disease management took a significant step toward modernization. The Celiac Disease Foundation (CDF) and the Society for the Study of Celiac Disease (SSCD) jointly hosted the "2026 National Celiac Disease Policy Symposium: From Diagnosis to Coverage." This pivotal virtual summit served as a bridge between the clinical laboratory and the boardroom, bringing together the industry’s most influential voices—from drug developers and diagnostic experts to federal regulators and health insurance "payers"—to ensure that when the next generation of celiac therapeutics reaches the market, the infrastructure for patient access is already in place.

The Urgency of Policy Alignment

For decades, the standard of care for celiac disease has been limited to a strict, lifelong gluten-free diet. While effective for symptom management, it is a demanding regimen that does not address the underlying autoimmune pathology for many patients. With several therapeutic candidates currently moving through advanced clinical trials, the medical community is bracing for a paradigm shift.

However, clinical efficacy is only half the battle. The symposium’s core message was clear: without a robust policy framework, even the most effective breakthrough drugs could be stalled by hurdles in insurance coverage, confusing diagnostic criteria, and inconsistent regulatory standards. The symposium aimed to synchronize these disparate sectors to prevent the "access gap" that often plagues rare and autoimmune conditions.

Chronology of the Symposium: A Deep Dive into the Regulatory Pipeline

The day-long event was structured to mirror the journey of a patient—from the initial diagnostic encounter to the complex world of insurance reimbursement and long-term advocacy.

Panel 1: Diagnostic Alignment in a Therapeutic Era

Moderated by experts including Dr. Christopher Cao and Dr. Marie Robert, this session addressed a fundamental problem: not all celiac diagnoses are created equal. As we enter a "therapeutic era," the precision of initial testing becomes paramount. Insurance providers often require rigorous documentation to approve specialty drugs; if a patient’s initial biopsy or serology results are incomplete or improperly documented, they may face denials.

• Action Item for Patients: The panel urged attendees to secure their complete medical records now. If you were diagnosed years ago, check your files for original biopsy reports and blood test results. If these are missing, consult your physician about diagnostic "clarification" procedures.

Panel 2: Trial Design, Genotype, and Regulatory Signals

Clinical trials rely heavily on patient stratification, particularly regarding HLA-DQ2/DQ8 genotypes. Dr. Edwin Liu and his colleagues explored how genetic testing—often treated as a secondary diagnostic tool—must now be viewed as a gateway to clinical trial eligibility. Understanding one’s specific HLA alleles is no longer just for diagnostic confirmation; it is the key to unlocking participation in the next generation of drug trials.

• Action Item for Patients: Move beyond the simple "positive/negative" result. Request the full report detailing your specific alleles. This data is essential for both your clinical record and potential future trial recruitment.

Panel 3: Defining Treatment-Eligible Celiac Disease

Perhaps the most contentious segment of the day involved defining who "needs" a drug. The panel, featuring Dr. Ben Lebwohl and Dr. Anne Lee, debated the criteria for eligibility. Should access be limited to those with refractory celiac disease, or should it include those who remain symptomatic despite a strict diet? The consensus pointed toward a multifaceted approach: documenting not just test results, but "lived experience"—the ongoing symptoms, nutritional deficiencies, and the immense psychological and social burden of the gluten-free diet.

• Action Item for Patients: Start a "burden of disease" journal. Document symptoms, quality-of-life impacts, and nutritional status. Regular evaluations by a specialized dietitian—at least twice a year—are highly recommended to create a longitudinal record that may be vital for future insurance claims.

Panel 4: Payer Coverage Strategy

The most pragmatic session involved representatives from the insurance sector, including Jonathan Blum and Dr. Alexander Oshmyansky. They outlined the brutal reality of "evidence-based coverage." Payers require standardized data to justify the high costs of specialty therapeutics. They look for specific biomarkers, consistent adherence to clinical guidelines, and clear demonstrations of therapeutic necessity.

• Action Item for Patients: For those employed by self-insured organizations, the panel noted that your employer often has a direct hand in selecting what the company’s health plan covers. Engaging with HR or benefits administrators about the necessity of coverage for emerging celiac treatments could be an overlooked but powerful advocacy tool.

Panel 5 and Closing: Advocacy Roadmaps

The symposium concluded with lessons learned from other autoimmune conditions, such as Crohn’s disease and Type 1 Diabetes. The message was optimistic but sobering: advocacy is a marathon. By observing how these patient communities successfully lobbied for coverage, the celiac community can develop a roadmap to ensure that once a drug receives FDA approval, it does not sit in a "coverage limbo" for years.

Supporting Data: Why the Need is Critical

The urgency of this symposium is supported by the increasing volume of celiac research. With multiple therapeutics in Phase II and Phase III trials, the potential for a pharmaceutical treatment for celiac disease is higher today than at any point in history.

However, the "data gap" remains a significant obstacle. Insurance companies operate on actuarial data; if there is no standardized, digital registry of celiac patient outcomes, the risk of "prior authorization" delays increases exponentially. The symposium emphasized that digital health records and standardized patient reporting are not just "nice to have"—they are the foundation upon which future drug access will be built.

Official Responses and Industry Commitment

The symposium highlighted a remarkable alignment between pharmaceutical sponsors and patient advocacy groups. Sponsors including Takeda Pharmaceuticals, Forte Biosciences, Chugai Pharmaceuticals, and First Tracks Biotherapeutics emphasized that their investment in research is only half of their responsibility.

"We are not just developing molecules; we are developing solutions for a community," noted representatives during the closing plenary. "The goal is to ensure that by the time these drugs are approved, the payer environment is ready to receive them."

The Celiac Disease Foundation (CDF) reaffirmed its commitment to acting as a liaison between the patient population, the federal government, and the private insurance industry. Their role is to ensure that the voice of the patient—who has long dealt with the daily reality of a restrictive, non-negotiable diet—is heard by those who sign the coverage checks.

Implications for the Future

The 2026 Symposium effectively signaled the end of the "diet-only" mindset in the celiac space. The implications for the average patient are twofold:

1. Professionalization of Personal Health Management: Patients are being encouraged to move from passive recipients of care to active managers of their medical data. The importance of having high-quality, digitized, and accessible health records cannot be overstated.
2. The Rise of Targeted Advocacy: The symposium provided a blueprint for how patients can push back against restrictive insurance policies. By documenting the "lived experience" of the disease and understanding the leverage points within self-insured employment models, the community is better prepared to advocate for their own treatment access.

As the industry looks toward the next 18 to 24 months, the collaboration between the CDF, clinicians, and payers will likely intensify. The "From Diagnosis to Coverage" initiative is more than a one-day event; it is the beginning of a long-term campaign to ensure that medical innovation is matched by equitable access.

For patients who missed the live event, the full recordings are available on the Celiac Disease Foundation website. In an era of rapid medical advancement, staying informed is the first step toward securing the future of celiac care.